Halozyme Therapeutics | HALO - Despesas Operacionais





Despesas Operacionais Alterar Data
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amarin USD 51.48M 113K 2025-12
Amgen USD 4.78B 1.12B 2026-03
Baxter International USD 6.04B 2.85B 2026-03
Cara Therapeutics USD 5.94M 983K 2025-09
Cytokinetics USD 200.58M 4.46M 2026-03
DBV Technologies USD 37.05M 4.06M 2025-09
Eli Lilly USD 10.02B 285M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Intrexon USD 61.56M 26.1M 2024-06
Ionis Pharmaceuticals USD 364M 54M 2026-03
MannKind USD 110.9M 8.74M 2026-03
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
United Therapeutics USD 5.9B 5.1B 2026-03
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12